ICON9: A study evaluating the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this clinical trial if you:
-
ovarian, fallopian tube or primary peritoneal cancer of high grade serous or endometrioid type.
-
cancer that was sensitive to platinum-based first-line chemotherapy (carboplatin or cisplatin chemotherapy.) Platinum-sensitive means that the patient had not needed treatment within six months of having platinum-based chemotherapy and the cancer had responded to this chemotherapy.
-
recently had at least four cycles of platinum-based chemotherapy for a recurrence of the cancer and the cancer is showing a response to that chemotherapy.
-
not had treatment with a PARP inhibitor or VEGF inhibitor in the past.
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
This trial looks to answer the question as to whether two different types of anti-cancer drugs, given as maintenance treatment are:
-
safe
-
effective
-
well-tolerated
Maintenance treatment is a type of targeted therapy that is given to try to prevent or delay the cancer's return after it has responded to chemotherapy.
The drugs involved in this trial are:
-
Olaparib – a PARP inhibitor
-
Cediranib – a VEGF inhibitor
If you take part in this study, you'll be randomised (placed into a treatment group by a computer) into one of two treatment groups:
-
Oral olaparib 300mg twice daily and cediranib 20mg once daily
-
Oral olaparib 300mg twice daily
